Benefit with MRD-guided treatment in CLL

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-01-02 DOI:10.1038/s41571-023-00858-8

Diana Romero

引用次数: 0

查看原文本刊更多论文

MRD指导下的治疗对CLL的益处

慢性淋巴细胞白血病（CLL）患者通常接受氟达拉滨、环磷酰胺和利妥昔单抗（FCR）的一线治疗，但在过去十年中，其他药物也显示出了良好的疗效。这些疗法包括 BTK 抑制剂 ibrutinib 和 BCL2 拮抗剂 venetoclax 的联合治疗。现在，III 期 FLAIR 试验的结果表明，在通过监测可测量的残留疾病（MRD）来确定治疗时间的情况下，这种联合疗法具有优越性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.